# iQSTEL Inc: financial statements, quarterly

IQST · Nasdaq · CIK 1527702 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iqst.md) · [Financials](/companies/iqst/financials.md) · [Filings](/companies/iqst/filings.md) · [Insiders](/companies/iqst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/iqst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [39.8](/filings/0001663577-24-000281.md) | [47.3 d](/filings/0001663577-25-000086.md) | [51.4](/filings/0001663577-25-000148.md) | [78.6](/filings/0001663577-25-000264.md) | [54.2](/filings/0001663577-25-000314.md) | [98.9 d](/filings/0001663577-26-000094.md) | [57.6](/filings/0001663577-26-000154.md) | [72.2](/filings/0001663577-26-000258.md) | [103](/filings/0001663577-25-000314.md) | [84.2 d](/filings/0001663577-26-000094.md) | [97.9](/filings/0001663577-26-000154.md) | [109](/filings/0001663577-26-000258.md) |
| Cost of revenue | $m | [38.7](/filings/0001663577-24-000281.md) | [45.6 d](/filings/0001663577-25-000086.md) | [50.0](/filings/0001663577-25-000148.md) | [76.5](/filings/0001663577-25-000264.md) | [52.2](/filings/0001663577-25-000314.md) | [96.2 d](/filings/0001663577-26-000094.md) | [55.7](/filings/0001663577-26-000154.md) | [70.3](/filings/0001663577-26-000258.md) | [100](/filings/0001663577-25-000314.md) | [81.3 d](/filings/0001663577-26-000094.md) | [95.8](/filings/0001663577-26-000154.md) | [106](/filings/0001663577-26-000258.md) |
| Gross profit | $m | [1.0](/filings/0001663577-24-000281.md) | [1.6 d](/filings/0001663577-25-000086.md) | [1.4](/filings/0001663577-25-000148.md) | [2.2](/filings/0001663577-25-000264.md) | [2.0](/filings/0001663577-25-000314.md) | [2.7 d](/filings/0001663577-26-000094.md) | [1.9](/filings/0001663577-26-000154.md) | [1.9](/filings/0001663577-26-000258.md) | [2.7](/filings/0001663577-25-000314.md) | [2.9 d](/filings/0001663577-26-000094.md) | [2.1](/filings/0001663577-26-000154.md) | [2.7](/filings/0001663577-26-000258.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [0.1](/filings/0001663577-24-000281.md) | [0.2 d](/filings/0001663577-25-000086.md) | [(0.2)](/filings/0001663577-25-000148.md) | [(0.3)](/filings/0001663577-25-000264.md) | [(0.1)](/filings/0001663577-25-000314.md) | [(0.3) d](/filings/0001663577-26-000094.md) | [(0.6)](/filings/0001663577-26-000154.md) | [(0.7)](/filings/0001663577-26-000258.md) | [(0.6)](/filings/0001663577-25-000314.md) | [(2.4) d](/filings/0001663577-26-000094.md) | [(1.0)](/filings/0001663577-26-000154.md) | [(1.1)](/filings/0001663577-26-000258.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001663577-26-000258.md) | not reported | not reported | not reported | [0.2](/filings/0001663577-26-000258.md) |
| Income tax | $m | not reported | not reported | not reported | [0.1](/filings/0001663577-25-000264.md) | [0.1](/filings/0001663577-25-000314.md) | [0.3 d](/filings/0001663577-26-000094.md) | [0.0](/filings/0001663577-26-000154.md) | [0.1](/filings/0001663577-26-000258.md) | [0.1](/filings/0001663577-25-000314.md) | [(0.1) d](/filings/0001663577-26-000094.md) | [0.0](/filings/0001663577-26-000154.md) | [0.1](/filings/0001663577-26-000258.md) |
| Net income | $m | [0.0](/filings/0001663577-24-000281.md) | [(0.5) d](/filings/0001663577-25-000086.md) | [(0.6)](/filings/0001663577-25-000314.md) | [(2.0)](/filings/0001663577-25-000314.md) | [(0.8)](/filings/0001663577-25-000314.md) | [(1.9) d](/filings/0001663577-26-000094.md) | [(1.1)](/filings/0001663577-26-000258.md) | [(2.3)](/filings/0001663577-26-000258.md) | [(2.3)](/filings/0001663577-25-000314.md) | [(2.7) d](/filings/0001663577-26-000094.md) | [(1.4)](/filings/0001663577-26-000258.md) | [(2.4)](/filings/0001663577-26-000258.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001663577-24-000281.md) | not reported | [(0.37)](/filings/0001663577-25-000148.md) | [(0.90)](/filings/0001663577-25-000264.md) | [(0.40)](/filings/0001663577-25-000314.md) | not reported | [(0.44)](/filings/0001663577-26-000154.md) | [(0.82)](/filings/0001663577-26-000258.md) | [(0.68)](/filings/0001663577-25-000314.md) | not reported | [(0.29)](/filings/0001663577-26-000154.md) | [(0.38)](/filings/0001663577-26-000258.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.0](/filings/0001663577-23-000520.md) | [1.4](/filings/0001663577-25-000086.md) | [2.7](/filings/0001663577-24-000133.md) | [0.8](/filings/0001663577-24-000224.md) | [2.1](/filings/0001663577-24-000281.md) | [2.5](/filings/0001663577-26-000094.md) | [1.1](/filings/0001663577-25-000148.md) | [2.0](/filings/0001663577-25-000264.md) | [2.3](/filings/0001663577-25-000314.md) | [2.2](/filings/0001663577-26-000258.md) | [2.6](/filings/0001663577-26-000154.md) | [2.1](/filings/0001663577-26-000258.md) |
| Current assets | $m | [11.8](/filings/0001663577-23-000520.md) | [15.7](/filings/0001663577-25-000086.md) | [15.6](/filings/0001663577-24-000133.md) | [17.2](/filings/0001663577-24-000224.md) | [19.7](/filings/0001663577-24-000281.md) | [63.0](/filings/0001663577-26-000094.md) | [26.0](/filings/0001663577-25-000148.md) | [35.6](/filings/0001663577-25-000264.md) | [29.8](/filings/0001663577-25-000314.md) | [36.2](/filings/0001663577-26-000258.md) | [29.7](/filings/0001663577-26-000154.md) | [33.5](/filings/0001663577-26-000258.md) |
| Total assets | $m | [18.1](/filings/0001663577-23-000520.md) | [22.2](/filings/0001663577-25-000086.md) | [22.1](/filings/0001663577-24-000133.md) | [30.0](/filings/0001663577-24-000224.md) | [32.4](/filings/0001663577-24-000281.md) | [79.0](/filings/0001663577-26-000094.md) | [42.0](/filings/0001663577-25-000148.md) | [51.4](/filings/0001663577-25-000264.md) | [46.9](/filings/0001663577-25-000314.md) | [51.1](/filings/0001663577-26-000258.md) | [44.5](/filings/0001663577-26-000154.md) | [48.2](/filings/0001663577-26-000258.md) |
| Current liabilities | $m | [9.9](/filings/0001663577-23-000520.md) | [13.8](/filings/0001663577-25-000086.md) | [13.5](/filings/0001663577-24-000133.md) | [22.2](/filings/0001663577-24-000224.md) | [24.1](/filings/0001663577-24-000281.md) | [63.8](/filings/0001663577-26-000094.md) | [30.3](/filings/0001663577-25-000148.md) | [36.8](/filings/0001663577-25-000264.md) | [28.7](/filings/0001663577-25-000314.md) | [34.6](/filings/0001663577-26-000258.md) | [30.0](/filings/0001663577-26-000154.md) | [30.8](/filings/0001663577-26-000258.md) |
| Total liabilities | $m | [10.2](/filings/0001663577-23-000520.md) | [14.1](/filings/0001663577-25-000086.md) | [13.7](/filings/0001663577-24-000133.md) | [22.4](/filings/0001663577-24-000224.md) | [24.3](/filings/0001663577-24-000281.md) | [67.1](/filings/0001663577-26-000094.md) | [30.5](/filings/0001663577-25-000148.md) | [37.1](/filings/0001663577-25-000264.md) | [29.0](/filings/0001663577-25-000314.md) | [34.8](/filings/0001663577-26-000258.md) | [30.2](/filings/0001663577-26-000154.md) | [31.0](/filings/0001663577-26-000258.md) |
| Long-term debt | $m | [0.1](/filings/0001663577-23-000520.md) | [0.1](/filings/0001663577-25-000086.md) | [0.1](/filings/0001663577-24-000133.md) | [2.5](/filings/0001663577-24-000224.md) | [3.2](/filings/0001663577-24-000281.md) | [2.5](/filings/0001663577-26-000094.md) | [3.5](/filings/0001663577-25-000148.md) | [4.5](/filings/0001663577-25-000264.md) | [0.0](/filings/0001663577-25-000314.md) | [0.0](/filings/0001663577-26-000258.md) | [0.0](/filings/0001663577-26-000154.md) | [0.0](/filings/0001663577-26-000258.md) |
| Current portion of debt | $m | [0.3](/filings/0001663577-23-000520.md) | [0.3](/filings/0001663577-25-000086.md) | [0.1](/filings/0001663577-24-000133.md) | [2.5](/filings/0001663577-24-000224.md) | [3.2](/filings/0001663577-24-000281.md) | [2.5](/filings/0001663577-26-000094.md) | [3.5](/filings/0001663577-25-000148.md) | [4.5](/filings/0001663577-25-000264.md) | [2.7](/filings/0001663577-25-000314.md) | [4.0](/filings/0001663577-26-000258.md) | [4.9](/filings/0001663577-26-000154.md) | [2.5](/filings/0001663577-26-000258.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [8.0](/filings/0001663577-24-000281.md) | [8.0](/filings/0001663577-26-000094.md) | [8.4](/filings/0001663577-25-000314.md) | [7.6](/filings/0001663577-25-000314.md) | [8.1](/filings/0001663577-25-000314.md) | [11.9](/filings/0001663577-26-000258.md) | [11.6](/filings/0001663577-26-000258.md) | [14.3](/filings/0001663577-26-000258.md) | [17.9](/filings/0001663577-25-000314.md) | [16.3](/filings/0001663577-26-000258.md) | [14.3](/filings/0001663577-26-000258.md) | [17.2](/filings/0001663577-26-000258.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [287 d](/filings/0001663577-24-000281.md) | [(1,049) d](/filings/0001663577-25-000086.md) | [(537)](/filings/0001663577-25-000148.md) | [(2,615) d](/filings/0001663577-25-000264.md) | [625 d](/filings/0001663577-25-000314.md) | [(404) d](/filings/0001663577-26-000094.md) | [(1,907)](/filings/0001663577-26-000154.md) | [258 d](/filings/0001663577-26-000258.md) | [(953) d](/filings/0001663577-25-000314.md) | [(1,243) d](/filings/0001663577-26-000094.md) | [(175)](/filings/0001663577-26-000154.md) | [(1,492) d](/filings/0001663577-26-000258.md) |
| Capital expenditure | $k | [32.5 d](/filings/0001663577-24-000281.md) | [55.3 d](/filings/0001663577-25-000086.md) | [71.7](/filings/0001663577-25-000148.md) | [31.8 d](/filings/0001663577-25-000264.md) | [30.5 d](/filings/0001663577-25-000314.md) | [17.6 d](/filings/0001663577-26-000094.md) | [49.2](/filings/0001663577-26-000154.md) | [46.0 d](/filings/0001663577-26-000258.md) | [16.2 d](/filings/0001663577-25-000314.md) | [1.6 d](/filings/0001663577-26-000094.md) | [1.4](/filings/0001663577-26-000154.md) | [1.7 d](/filings/0001663577-26-000258.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2019 (2019-06-30) | Q2 FY2020 (2020-06-30) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [15.4](/filings/0001078782-20-000625.md) | [68.6](/filings/0001078782-20-000625.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,915,859 at 2026-08-18, from the cover of the [10-Q/A filed 2026-08-20](/filings/0001663577-26-000258.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.